Compositions and methods to inhibit kidney stone growth
AssigneeKidney Stone Research Company, Inc.
InventorsGregory K. Hayer, Brendan Magrab, Henry R. Wolfe, Jr.
Life of this patent
Estimating the term…
Abstract
An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.
Claims19
A method of promoting kidney health in a subject, comprising administering to a subject an oral dosage form or plurality of dosage forms comprising four active ingredients selected from citric acid, magnesium citrate, phytin, pyridoxine, and musa, wherein the oral dosage form or plurality of dosage forms is selected from:
- a) an oral dosage form or plurality of dosage forms wherein citric acid is present in an amount of about 101 mg to about 699 mg, magnesium citrate is present in an amount of about 77 mg to about 227 mg, phytin is present in an amount of about 3.06 mg to about 600 mg, and pyridoxine is present in an amount of about 0.23 mg to about 15.13 mg, wherein the percent inhibition of calcium oxalate crystal formation by the combination of active ingredients is greater than about 89%;
- b) an oral dosage form or plurality of dosage forms wherein citric acid is present in an amount of about 102 mg to about 1052 mg, magnesium citrate is present in an amount of about 2.32 mg to about 201 mg, phytin is present in an amount of about 100 mg to about 600 mg, and musa is present in an amount of about 1.51 mg to about 251 mg, wherein the percent inhibition of calcium oxalate crystal formation by the combination of active ingredients is greater than about 92%;
- c) an oral dosage form or plurality of dosage forms wherein citric acid is present in an amount of about 101 mg to about 1051 mg, magnesium citrate is present in an amount of about 2.14 mg to about 226 mg, pyridoxine is present in an amount of about 0.25 mg to about 10.23 mg, and musa is present in an amount of about 41 mg to about 252 mg, wherein the percent inhibition of calcium oxalate crystal formation by the combination of active ingredients is greater than about 59%;
- d) an oral dosage form or plurality of dosage forms wherein citric acid is present in an amount of about 101 mg to less than about 700 mg, phytin is present in an amount of about 101 mg to about 600 mg, pyridoxine is present in an amount of about 0.23 mg to about 15.12 mg, and musa is present in an amount of about 1.46 mg to about 252 mg, wherein the percent inhibition of calcium oxalate crystal formation by the combination of active ingredients is greater than about 88%;
- and
- e) an oral dosage form or plurality of dosage forms wherein magnesium citrate is present in an amount of about 2.03 mg to about 203 mg, phytin is present in an amount of about 100 mg to about 600 mg, pyridoxine is present in an amount of about 0.22 mg to about 15.1 mg, and musa is present in an amount of about 1.46 mg to about 252 mg, wherein the percent inhibition of calcium oxalate crystal formation by the combination of active ingredients is greater than about 99%.
A method of inhibiting the rate of formation of calcium oxalate in a subject, comprising administering to a subject an oral dosage form or plurality of dosage forms comprising four active ingredients selected from citric acid, magnesium citrate, phytin, pyridoxine, and musa, wherein the oral dosage form or plurality of dosage forms is selected from:
- a) an oral dosage form or plurality of dosage forms wherein citric acid is present in an amount of about 101 mg to about 699 mg, magnesium citrate is present in an amount of about 77 mg to about 227 mg, phytin is present in an amount of about 3.06 mg to about 600 mg, and pyridoxine is present in an amount of about 0.23 mg to about 15.13 mg, wherein the percent inhibition of calcium oxalate crystal formation by the combination of active ingredients is greater than about 89%;
- b) an oral dosage form or plurality of dosage forms wherein citric acid is present in an amount of about 102 mg to about 1052 mg, magnesium citrate is present in an amount of about 2.32 mg to about 201 mg, phytin is present in an amount of about 100 mg to about 600 mg, and musa is present in an amount of about 1.51 mg to about 251 mg, wherein the percent inhibition of calcium oxalate crystal formation by the combination of active ingredients is greater than about 92%;
- c) an oral dosage form or plurality of dosage forms wherein citric acid is present in an amount of about 101 mg to about 1051 mg, magnesium citrate is present in an amount of about 2.14 mg to about 226 mg, pyridoxine is present in an amount of about 0.25 mg to about 10.23 mg, and musa is present in an amount of about 41 mg to about 252 mg, wherein the percent inhibition of calcium oxalate crystal formation by the combination of active ingredients is greater than about 59%;
- d) an oral dosage form or plurality of dosage forms wherein citric acid is present in an amount of about 101 mg to less than about 700 mg, phytin is present in an amount of about 101 mg to about 600 mg, pyridoxine is present in an amount of about 0.23 mg to about 15.12 mg, and musa is present in an amount of about 1.46 mg to about 252 mg, wherein the percent inhibition of calcium oxalate crystal formation by the combination of active ingredients is greater than about 88%;
- and
- e) an oral dosage form or plurality of dosage forms wherein magnesium citrate is present in an amount of about 2.03 mg to about 203 mg, phytin is present in an amount of about 100 mg to about 600 mg, pyridoxine is present in an amount of about 0.22 mg to about 15.1 mg, and musa is present in an amount of about 1.46 mg to about 252 mg, wherein the percent inhibition of calcium oxalate crystal formation by the combination of active ingredients is greater than about 99%.
Dependencies are inferred from the claim text.